John Mendlein

Insider Reports History

Signature
/s/ Cindy Tahl, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by John Mendlein:

Stock Role Class Num Shares Value Price $ Report Date Ownership
FATE THERAPEUTICS INC Director Stock Option (Right to Buy) 55K $109K $2.73 May 29, 2025 Direct
Omega Therapeutics, Inc. Director Stock Option (Right to Buy) 25K Jun 20, 2024 Direct

Insider Reports Filed by John Mendlein

Symbol Company Period Transactions Value $ Form Type Date Filed Role
FATE FATE THERAPEUTICS INC May 29, 2025 1 $0 4 May 30, 2025 Director
OMGA Omega Therapeutics, Inc. Jun 20, 2024 1 $0 4 Jun 21, 2024 Director
FATE FATE THERAPEUTICS INC Jun 7, 2024 1 $0 4 Jun 11, 2024 Director
OMGA Omega Therapeutics, Inc. Jun 7, 2023 1 $0 4 Jun 9, 2023 Director
FATE FATE THERAPEUTICS INC Jun 6, 2023 1 $0 4 Jun 7, 2023 Director
FATE FATE THERAPEUTICS INC Jan 19, 2023 2 $39K 4 Jan 20, 2023 Director
FATE FATE THERAPEUTICS INC Jan 11, 2023 2 $698K 4 Jan 13, 2023 Director
FATE FATE THERAPEUTICS INC Jun 9, 2022 2 $0 4 Jun 13, 2022 Director
OMGA Omega Therapeutics, Inc. Jun 8, 2022 1 $0 4 Jun 10, 2022 Director
FATE FATE THERAPEUTICS INC Jun 3, 2022 1 -$31.1K 4 Jun 6, 2022 Director
FATE FATE THERAPEUTICS INC Mar 10, 2022 4 -$1.05M 4 Mar 11, 2022 Director
OMGA Omega Therapeutics, Inc. Jul 29, 2021 0 $0 3 Jul 29, 2021 Director
FATE FATE THERAPEUTICS INC Jun 2, 2021 2 $0 4 Jun 4, 2021 Director